Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

ACADIA Pharmaceuticals Inc. (ACAD)

Compare
16.32
-0.29
(-1.75%)
At close: April 1 at 4:00:01 PM EDT
16.79
+0.47
+(2.88%)
Pre-Market: 4:26:04 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
957,797
957,797
726,437
517,235
484,145
Cost of Revenue
81,841
81,841
41,638
10,166
19,141
Gross Profit
875,956
875,956
684,799
507,069
465,004
Operating Expense
791,677
791,677
758,178
730,665
635,443
Operating Income
84,279
84,279
-73,379
-223,596
-170,439
Net Non Operating Interest Income Expense
25,458
25,458
17,234
6,610
591
Other Income Expense
148,338
148,338
5,109
3,542
2,329
Pretax Income
258,075
258,075
-51,036
-213,444
-167,519
Tax Provision
31,624
31,624
10,250
2,531
351
Net Income Common Stockholders
226,451
226,451
-61,286
-215,975
-167,870
Diluted NI Available to Com Stockholders
226,451
226,451
-61,286
-215,975
-167,870
Basic EPS
0.78
1.37
-0.37
-1.34
-1.05
Diluted EPS
0.78
1.36
-0.37
-1.34
-1.05
Basic Average Shares
165,285.25
165,717
163,819
161,683
160,493
Diluted Average Shares
165,805
166,362
163,819
161,683
160,493
Total Operating Income as Reported
230,794
230,794
-73,379
-223,596
-170,439
Total Expenses
873,518
873,518
799,816
740,831
654,584
Net Income from Continuing & Discontinued Operation
226,451
226,451
-61,286
-215,975
-167,870
Normalized Income
97,889.66
97,889.66
-61,286
-215,975
-167,870
Interest Income
25,458
25,458
17,234
6,610
591
Net Interest Income
25,458
25,458
17,234
6,610
591
EBIT
84,279
84,279
-73,379
-223,596
-170,439
EBITDA
100,162
100,162
-67,827
-221,570
-167,095
Reconciled Cost of Revenue
81,841
81,841
41,638
10,166
19,141
Reconciled Depreciation
15,883
15,883
5,552
2,026
3,344
Net Income from Continuing Operation Net Minority Interest
226,451
226,451
-61,286
-215,975
-167,870
Total Unusual Items Excluding Goodwill
146,515
146,515
--
--
--
Total Unusual Items
146,515
146,515
--
--
--
Normalized EBITDA
-46,353
-46,353
-67,827
-221,570
-167,095
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
17,953.66
17,953.66
--
--
--
12/31/2021 - 5/27/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RARE Ultragenyx Pharmaceutical Inc.
33.84
-6.55%
 
INCY Incyte Corporation
60.91
+0.59%
 
FOLD Amicus Therapeutics, Inc.
7.95
-2.57%
 
BCYC Bicycle Therapeutics plc
7.85
-7.54%
 
BMRN BioMarin Pharmaceutical Inc.
67.94
-3.89%
 
NEU.AX Neuren Pharmaceuticals Limited
10.81
-4.76%
 
IONS Ionis Pharmaceuticals, Inc.
27.26
-9.65%
 
RYTM Rhythm Pharmaceuticals, Inc.
50.00
-5.61%
 
SAGE Sage Therapeutics, Inc.
7.86
-1.13%
 
VNDA Vanda Pharmaceuticals Inc.
4.5000
-1.96%